Instil Bio, Inc. (TIL) Current Ratio
- Current ratio · latest quarter: Value 21.67×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 21.67× | Current assets / current liabilities. $71.61M ÷ $3.31M ≈ 21.67× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 71.61M USD | Assets, Current |
| Current obligations | 3.31M USD | Liabilities, Current |
| Cash and equivalents | 5.54M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 795.00K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $71.61M | $3.31M | $5.54M | (m) | (m) | (m) | $795.00K | (m) | 21.67× |
| 2026-03-31 | $188.30M | $4.72M | $5.02M | (m) | (m) | (m) | $793.00K | (m) | 39.87× |
| 2025-12-31 | $191.43M | $4.84M | $6.64M | (m) | (m) | (m) | $779.00K | (m) | 39.53× |
| 2025-09-30 | $196.26M | $5.70M | $5.80M | (m) | (m) | (m) | $928.00K | (m) | 34.45× |
| 2025-06-30 | $207.39M | $13.85M | $7.69M | (m) | (m) | (m) | $523.00K | (m) | 14.97× |
| 2025-03-31 | $219.26M | $7.23M | $15.37M | (m) | (m) | (m) | $286.00K | (m) | 30.33× |
| 2024-12-31 | $124.47M | $7.90M | $8.80M | (m) | (m) | (m) | $659.00K | (m) | 15.76× |
| 2024-09-30 | $132.57M | $10.28M | $6.66M | (m) | (m) | (m) | $1.20M | (m) | 12.90× |
| 2024-06-30 | $154.93M | $10.29M | $6.78M | (m) | (m) | (m) | $1.22M | (m) | 15.06× |
| 2024-03-31 | $161.03M | $11.35M | $5.48M | (m) | (m) | (m) | $1.23M | (m) | 14.19× |
| 2023-12-31 | $160.76M | $10.56M | $9.20M | (m) | (m) | (m) | $1.21M | (m) | 15.22× |
| 2023-09-30 | $195.63M | $13.47M | $9.13M | $174.31M | (m) | (m) | $1.65M | (m) | 14.53× |
| 2023-06-30 | $220.59M | $18.38M | $21.76M | $179.94M | (m) | (m) | $2.16M | (m) | 12.00× |
| 2023-03-31 | $240.12M | $26.69M | $27.35M | $195.84M | (m) | (m) | $1.35M | (m) | 9.00× |
| 2022-12-31 | $269.38M | $32.79M | $43.72M | $217.20M | (m) | (m) | $2.36M | (m) | 8.22× |
| 2022-09-30 | $313.66M | $42.10M | $41.12M | $262.17M | (m) | (m) | $5.33M | (m) | 7.45× |
| 2022-06-30 | $367.68M | $43.21M | $42.46M | $312.14M | (m) | (m) | $5.79M | (m) | 8.51× |
| 2022-03-31 | $390.70M | $36.78M | $61.47M | $318.05M | (m) | (m) | $7.71M | (m) | 10.62× |
| 2021-12-31 | $464.02M | $41.36M | $37.59M | $416.51M | (m) | (m) | $5.57M | (m) | 11.22× |
| 2021-09-30 | $523.09M | $32.09M | $20.40M | $494.96M | (m) | (m) | $5.25M | (m) | 16.30× |
| 2021-06-30 | $574.46M | $23.84M | $566.73M | (m) | (m) | (m) | $5.22M | (m) | 24.09× |
| 2021-03-31 | $613.76M | $17.32M | $609.64M | (m) | (m) | (m) | $3.73M | (m) | 35.43× |
| 2020-12-31 | $246.14M | $13.28M | $241.71M | $0.00 | (m) | (m) | $3.50M | (m) | 18.53× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |